153 related articles for article (PubMed ID: 29262742)
1. Efficacy and safety of voriconazole in immunocompromised patients: systematic review and meta-analysis.
Rosanova MT; Bes D; Serrano Aguilar P; Sberna N; Lede R
Infect Dis (Lond); 2018 Jul; 50(7):489-494. PubMed ID: 29262742
[TBL] [Abstract][Full Text] [Related]
2. Comparison of Antifungal Prophylaxis Drugs in Patients With Hematological Disease or Undergoing Hematopoietic Stem Cell Transplantation: A Systematic Review and Network Meta-analysis.
Wang J; Zhou M; Xu JY; Zhou RF; Chen B; Wan Y
JAMA Netw Open; 2020 Oct; 3(10):e2017652. PubMed ID: 33030550
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of posaconazole for the prevention of invasive fungal infections in immunocompromised patients: a systematic review with meta-analysis and trial sequential analysis.
Wong TY; Loo YS; Veettil SK; Wong PS; Divya G; Ching SM; Menon RK
Sci Rep; 2020 Sep; 10(1):14575. PubMed ID: 32884060
[TBL] [Abstract][Full Text] [Related]
4. Voriconazole prophylaxis in leukemic patients: A retrospective single-center study.
Bui V; Walker SA; Elligsen M; Vyas A; Kiss A; Palmay L
J Oncol Pharm Pract; 2020 Jun; 26(4):873-881. PubMed ID: 31566111
[TBL] [Abstract][Full Text] [Related]
5. Incidence of breakthrough fungal infections on isavuconazole prophylaxis compared to posaconazole and voriconazole.
Scott SA; Perry C; Mahmoudjafari Z; Martin GA; Boyd S; Thompson J; Thomas B
Transpl Infect Dis; 2023 Apr; 25(2):e14045. PubMed ID: 36856447
[TBL] [Abstract][Full Text] [Related]
6. A systematic review and meta-analysis of efficacy and safety of isavuconazole for the treatment and prophylaxis of invasive fungal infections.
Kato H; Hagihara M; Asai N; Umemura T; Hirai J; Mori N; Yamagishi Y; Iwamoto T; Mikamo H
Mycoses; 2023 Sep; 66(9):815-824. PubMed ID: 37300337
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of voriconazole as invasive fungal infection prophylaxis in patients with acute myeloid leukemia.
Machherndl-Spandl S; Vockenhuber T; Binder M; Weltermann A; Apfalter P; Lass-Flörl C; Girschikofsky M
Leuk Lymphoma; 2022 Oct; 63(10):2330-2335. PubMed ID: 35561263
[TBL] [Abstract][Full Text] [Related]
8. Breakthrough invasive fungal infections in liver transplant recipients exposed to prophylaxis with echinocandins vs other antifungal agents: A systematic review and meta-analysis.
Gatti M; Rinaldi M; Ferraro G; Toschi A; Caroccia N; Arbizzani F; Raschi E; Poluzzi E; Pea F; Viale P; Giannella M
Mycoses; 2021 Nov; 64(11):1317-1327. PubMed ID: 34387004
[TBL] [Abstract][Full Text] [Related]
9. Clinical study on empirical and diagnostic-driven (pre-emptive) therapy of voriconazole in severe aplastic anaemia patients with invasive fungal disease after intensive immunosuppressive therapy.
Wu Y; Yan L; Wang H; Liu H; Xing L; Fu R; Shao Z
Eur J Clin Microbiol Infect Dis; 2021 May; 40(5):949-954. PubMed ID: 33219473
[TBL] [Abstract][Full Text] [Related]
10. Combination antifungals as an effective means of salvage in paediatric leukaemia patients with invasive fungal infections.
Meena JP; Gupta AK; Jana M; Seth R
Indian J Med Microbiol; 2019; 37(1):109-112. PubMed ID: 31424020
[TBL] [Abstract][Full Text] [Related]
11. Successful challenge of voriconazole in a patient with posaconazole-associated minor drug eruption: A case report.
Weeraphon B; Vanichanan J; Usayaporn S
J Clin Pharm Ther; 2020 Dec; 45(6):1486-1488. PubMed ID: 32686229
[TBL] [Abstract][Full Text] [Related]
12. Comparative study of posaconazole and voriconazole for primary antifungal prophylaxis in patients with pediatric acute leukemia.
Tu S; Zhang K; Wang N; Chu J; Yang L; Xie Z
Sci Rep; 2023 Nov; 13(1):18789. PubMed ID: 37914820
[TBL] [Abstract][Full Text] [Related]
13. Broad spectrum triazoles for invasive mould infections in adults: Which drug and when?
Jenks JD; Mehta SR; Hoenigl M
Med Mycol; 2019 Apr; 57(Supplement_2):S168-S178. PubMed ID: 30816967
[TBL] [Abstract][Full Text] [Related]
14. Optimal trough concentration of voriconazole with therapeutic drug monitoring in children: A systematic review and meta-analysis.
Hanai Y; Hamada Y; Kimura T; Matsumoto K; Takahashi Y; Fujii S; Nishizawa K; Takesue Y
J Infect Chemother; 2021 Feb; 27(2):151-160. PubMed ID: 33376032
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness and antimicrobial susceptibility profiles during primary antimicrobial prophylaxis for pediatric acute myeloid leukemia.
Yeh TC; Hou JY; Huang TH; Lu CH; Sun FJ; Huang HM; Liu HC
Sci Rep; 2021 Oct; 11(1):21142. PubMed ID: 34707164
[TBL] [Abstract][Full Text] [Related]
16. Impact of oral voriconazole during chemotherapy for acute myeloid leukemia and myelodysplastic syndrome: a Japanese nationwide retrospective cohort study.
Tsutsumi I; Kunisawa S; Yoshida C; Seki M; Komeno T; Fushimi K; Morita S; Imanaka Y
Int J Clin Oncol; 2019 Nov; 24(11):1449-1458. PubMed ID: 31300904
[TBL] [Abstract][Full Text] [Related]
17. Disseminated fusariosis in immunocompromised children: a case series and review of literature.
Riojas Hernández MP; Cisneros Saldaña D; Vaquera Aparicio DN; Castillo Bejarano JI; Mascareñas de Los Santos AH; Villanueva-Lozano H; Treviño-Rangel Rogelio de J; De la O Cavazos ME
J Chemother; 2021 Dec; 33(8):519-527. PubMed ID: 33563140
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the Effectiveness of Additional Risk Minimization Measures for Voriconazole in the EU: Findings and Lessons Learned from a Healthcare Professional Survey.
Lem J; Younus M; Aram JA; Moosavi S; Freivogel K; Lewis A; Sobel RE
Pharmaceut Med; 2019 Apr; 33(2):121-133. PubMed ID: 31933256
[TBL] [Abstract][Full Text] [Related]
19. Potential voriconazole associated posterior reversible leukoencephalopathy in children with malignancies: Report of two cases.
Amanati A; Lotfi M; Manen RV; Faghihi MA; Yavarian M; Zekavat O; Badiee P; Mazinani NH; Bozorgi H
J Oncol Pharm Pract; 2021 Mar; 27(2):498-504. PubMed ID: 32689868
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of combination antifungal therapy in Korean haematological patients with invasive aspergillosis.
Lee DG; Lee HJ; Yan JL; Lin SS; Aram JA
Mycoses; 2019 Oct; 62(10):969-978. PubMed ID: 31355956
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
